Journal
ANTIOXIDANTS
Volume 11, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/antiox11010035
Keywords
melatonin; curcumin; folic acid; epigallocatechin gallate; sulforaphane; sodium butyrate; epidrugs; epigenetics; cancer; antioxidants
Ask authors/readers for more resources
In addition to genetic mutations, abnormal epigenetic changes play a crucial role in the development of head and neck cancer. Researchers are currently developing drugs, known as epidrugs, to correct these epigenetic alterations. Some compounds with antioxidant effects have been found to be effective in preventing malignant lesions and reducing complications from cytotoxic treatment. Studies have also shown promising results for certain compounds in the treatment of head and neck squamous cell carcinoma.
Along with genetic mutations, aberrant epigenetic alterations are the initiators of head and neck cancer carcinogenesis. Currently, several drugs are being developed to correct these epigenetic alterations, known as epidrugs. Some compounds with an antioxidant effect have been shown to be effective in preventing these malignant lesions and in minimizing the complications derived from cytotoxic treatment. Furthermore, in vitro and in vivo studies show a promising role in the treatment of head and neck squamous cell carcinoma (HNSCC). This is the case of supplements with DNA methylation inhibitory function (DNMTi), such as epigallocatechin gallate, sulforaphane, and folic acid; histone deacetylase inhibitors (HDACi), such as sodium butyrate and melatonin or histone acetyltransferase inhibitors (HATi), such as curcumin. The objective of this review is to describe the role of some antioxidants and their epigenetic mechanism of action, with special emphasis on melatonin and butyric acid given their organic production, in the prevention and treatment of HNSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available